Recommendations, evidence and sustainability of screening for pancreatic cancer in high-risk individuals
Pancreatic cancer is a highly lethal malignancy and is predicted to become the second
leading cause of cancer-related deaths by 2030. Early detection significantly improves …
leading cause of cancer-related deaths by 2030. Early detection significantly improves …
[HTML][HTML] Informatics strategies for early detection and risk mitigation in pancreatic cancer patients
This review provides a comprehensive overview of the current landscape in pancreatic
cancer (PC) screening, diagnosis, and early detection. This emphasizes the need for …
cancer (PC) screening, diagnosis, and early detection. This emphasizes the need for …
Integration of Germline Genetic Testing Into Routine Clinical Practice for Patients With Pancreatic Adenocarcinoma
KS Lau-Min, H Symecko, K Spielman, D Mann… - JCO Oncology …, 2024 - ascopubs.org
PURPOSE Germline genetic testing (GT) is recommended for all patients with pancreatic
ductal adenocarcinoma (PDAC), but the traditional clinical genetics infrastructure is limited …
ductal adenocarcinoma (PDAC), but the traditional clinical genetics infrastructure is limited …
Genetic medicine of familial and hereditary pancreatic cancer: Recent update in the era of precision cancer medicine
H Matsubayashi, Y Kiyozumi… - Journal of Hepato‐Biliary …, 2025 - Wiley Online Library
In Japan, 5 years have passed since the initiation of precision cancer medicine, and recent
data accumulation in familial pancreatic cancer (FPC) and hereditary pancreatic cancer is …
data accumulation in familial pancreatic cancer (FPC) and hereditary pancreatic cancer is …
[HTML][HTML] Hereditary Pancreatic Cancer: Advances in Genetic Testing, Early Detection Strategies, and Personalized Management
C Blanco Abad, P Gomila Pons… - Journal of Clinical …, 2025 - mdpi.com
Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with a
five-year survival rate of approximately 13% for advanced stages. While the majority of …
five-year survival rate of approximately 13% for advanced stages. While the majority of …
Bridging the Divide: From Universal Germline Testing Guidance to Real-World Implementation in Pancreatic Cancer Care.
H Singh, RD Nipp - JCO Oncology Practice, 2024 - europepmc.org
In this editorial accompanying manuscript the by Klatte and colleagues, Drs Singh, and Nipp
review the data behind universal germline testing in pancreatic adenocarcinoma, and …
review the data behind universal germline testing in pancreatic adenocarcinoma, and …